Sections

Pancreatic Cancer

Archetype A 23 regimens (Main Regimens) pancreatic

Pancreatic adenocarcinoma β€” localised to metastatic

DefinitionClick to collapse

Pancreatic adenocarcinoma is a malignant neoplasm arising from the exocrine pancreas, predominantly from the ductal epithelial cells. The pancreas is a retroperitoneal organ derived from the foregut (specifically, the dorsal and ventral pancreatic buds that fuse during embryological development). Anatomically, the pancreas is divided into four regions: the head (including the uncinate process), neck, body, and tail. The head lies within the curve of the duodenum and contains the ampulla of Vater, where the pancreatic and bile ducts converge. The neck is a short segment anterior to the superior mesenteric vessels. The body extends leftward and the tail reaches the splenic hilum. Pancreatic adenocarcinoma typically originates in the head or uncinate process (approximately 70-80% of cases) and is characterized by early local invasion of peripancreatic fat, nerves, and major vascular structures (e.g., superior mesenteric artery/vein, portal vein, celiac axis), as well as early metastasis to regional lymph nodes, liver, and peritoneum. The tumor often presents with obstructive jaundice (for head lesions), weight loss, abdominal pain, and new-onset diabetes. Histologically, it is usually a poorly differentiated adenocarcinoma with dense desmoplastic stroma. The disease is staged using the AJCC TNM system (8th edition), which incorporates tumor size, lymph node involvement, and distant metastasis. The clinical resectability status (resectable, borderline resectable, locally advanced, metastatic) is determined by multidisciplinary evaluation of high-quality cross-sectional imaging (pancreatic protocol CT or MRI) and its relationship to major peripancreatic vessels.

EpidemiologyClick to collapse

In 2026, an estimated 67,530 new cases of pancreatic cancer will be diagnosed in the United States (American Cancer Society, CA Cancer J Clin 2023). Globally, pancreatic cancer is the 12th most common cancer, with approximately 495,000 new cases annually (GLOBOCAN 2020).
Annual Incidence
Approximately 52,740 deaths from pancreatic cancer are projected in the United States in 2026, making it the fourth leading cause of cancer-related death. The 5-year overall survival rate for all stages combined is approximately 12%.
Annual Mortality
Incidence rates have been increasing over the past two decades, particularly among Black women, who have experienced the greatest increase compared to other demographic groups. Mortality rates have remained largely unchanged, reflecting the lack of effective early detection and treatments for advanced disease.
Trend & Projections
Pancreatic cancer incidence increases with age, with a median age at diagnosis of 70 years. Men have a slightly higher incidence than women (ratio approximately 1.2:1). Black individuals have a higher incidence and mortality compared to White individuals. Incidence also varies by geography, with higher rates in industrialized nations.
Demographics

SubtypesClick to collapse

Over 90% of pancreatic exocrine cancers.
Invasive Ductal Adenocarcinoma (Not Otherwise Specified)

The most common type, accounting for >90% of exocrine pancreatic malignancies. It arises from the pancreatic ductal epithelium and is characterized by glandular differentiation, marked desmoplasia, and early perineural invasion.

Approximately 1-4% of pancreatic adenocarcinomas.
Adenosquamous Carcinoma

A rare variant containing both glandular and squamous cell components. The squamous component must comprise at least 30% of the tumor for diagnosis.

Uncommon, <5% of invasive pancreatic cancers.
Colloid (Mucinous Noncystic) Carcinoma

Characterized by abundant extracellular mucin pools containing malignant epithelial cells. Often associated with an intraductal papillary mucinous neoplasm (IPMN) precursor.

Very rare, <1% of pancreatic cancers.
Hepatoid Carcinoma

A rare variant with histological features resembling hepatocellular carcinoma. It may produce alpha-fetoprotein (AFP).

Rare, <2% of pancreatic cancers.
Medullary Carcinoma

Characterized by large, poorly differentiated tumor cells with syncytial growth, pushing borders, and prominent lymphocytic infiltration. Often associated with microsatellite instability (MSI) and mismatch repair deficiency (dMMR).

Rare, <5% of pancreatic adenocarcinomas.
Undifferentiated (Anaplastic) Carcinoma

A highly aggressive variant with absence of glandular differentiation. May contain giant cells or be an undifferentiated carcinoma with osteoclast-like giant cells.

Extremely rare, <1% of pancreatic adenocarcinomas.
Signet Ring Cell Carcinoma

Characterized by cells with intracellular mucin vacuoles displacing the nucleus to the periphery, creating a 'signet ring' appearance.

Rare, <1% of pancreatic adenocarcinomas.
Micropapillary Carcinoma

An aggressive variant with small, hollow papillary tufts lacking fibrovascular cores, often present within retraction spaces.

Molecular PathogenesisClick to collapse

The molecular pathogenesis of pancreatic adenocarcinoma involves a stepwise accumulation of genetic and epigenetic alterations. The most common driver mutation is in the KRAS oncogene (present in >90% of cases), leading to constitutive activation of the RAS-MAPK signaling pathway, which promotes cell proliferation and survival. Inactivating mutations in tumor suppressor genes are also frequent: TP53 (>75% of cases), SMAD4 (DPC4, ~55%), and CDKN2A/p16 (~90% via deletion, mutation, or promoter methylation). The TGF-Ξ²/SMAD pathway is disrupted by SMAD4 loss, altering growth control and immune evasion. Other recurrently mutated genes include ARID1A, TGFBR2, and chromatin remodeling genes (e.g., MLL, MLL3, KMT2C). Homologous recombination repair genes, such as BRCA1, BRCA2, and PALB2, are mutated in approximately 5-7% of pancreatic adenocarcinomas, leading to genomic instability and sensitivity to platinum-based chemotherapies and PARP inhibitors. Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) occur in <2% of cases but are therapeutically relevant due to responsiveness to immune checkpoint inhibitors. Other actionable molecular alterations include NTRK gene fusions (<1%), BRAF V600E mutations (~1-2%), HER2 amplification (<5%), and RET fusions (<1%). These are identified via next-generation sequencing (NGS) and guide targeted therapy. Tumor mutational burden (TMB) is also assessed to predict immunotherapy response. The tumor microenvironment is characterized by a dense desmoplastic stroma, immunosuppressive cells, and hypovascularity, which contribute to chemoresistance.

Risk FactorsClick to collapse

Cigarette Smoking

Cigarette smoking is firmly linked to an increased risk of pancreatic cancer. The risk is proportional to the number of cigarettes smoked per day and duration of smoking. Approximately 20-25% of pancreatic cancers are attributable to smoking. Cessation of smoking reduces the risk over time.

Obesity and Physical Inactivity

Elevated body mass index (BMI) is associated with an increased risk, with a dose-response relationship. Higher BMI during early adulthood is linked to increased pancreatic cancer mortality. Low levels of physical activity also confer an increased risk.

Diabetes Mellitus

New-onset diabetes (within 3 years of pancreatic cancer diagnosis) may be a paraneoplastic syndrome caused by the cancer. Long-standing diabetes (β‰₯5 years) is a risk factor, though the association weakens with longer duration, possibly due to treatment effects. Prediabetes (impaired fasting glucose) is also associated with increased risk.

Chronic Pancreatitis
Hereditary Genetic Syndromes

Germline mutations in several genes confer increased risk, including BRCA1, BRCA2, PALB2, CDKN2A, MLH1, MSH2, MSH6, PMS2, STK11, ATM, and TP53. The lifetime risk for carriers of BRCA2 mutations is approximately 3-5%, and for Lynch syndrome genes it is around 3-4%.

Family History

A first-degree relative with pancreatic cancer increases the risk. The risk is further elevated with multiple affected relatives or early age of onset.

Heavy Alcohol Consumption

Heavy alcohol use (β‰₯3 drinks per day) is associated with an increased risk, possibly mediated through pancreatitis.

Periodontal Disease

Periodontal disease is associated with an increased risk, even after adjusting for other risk factors such as smoking and BMI.

Occupational Exposures

Exposure to certain chemicals and heavy metals, including beta-naphthylamine, benzidine, pesticides, asbestos, benzene, and chlorinated hydrocarbons, is associated with increased risk.

Low Vitamin D Levels

Some studies suggest an association between low plasma 25-hydroxyvitamin D levels and increased risk, but results are contradictory.

Clinical FeaturesClick to collapse

Typical Presentation

Pancreatic adenocarcinoma often presents late with non-specific symptoms, leading to delayed diagnosis. The classic presentation includes painless jaundice for tumors in the pancreatic head, weight loss, and new-onset diabetes. Symptoms often develop insidiously and are nonspecific, contributing to late-stage diagnosis [MS-5].

Symptoms

Common, especially for head lesions
Jaundice

Painless obstructive jaundice is a hallmark for pancreatic head tumors, caused by bile duct obstruction. It is often the presenting symptom leading to diagnosis.

Common, often at presentation
Abdominal pain

Dull, epigastric pain that may radiate to the back, often worse after meals and when lying down. Caused by tumor invasion of retroperitoneal nerves or obstruction of the pancreatic duct.

Very common, >80% of patients
Unintentional weight loss

Significant and unintentional weight loss is a frequent symptom, often due to malabsorption, anorexia, and catabolic state.

Common
Anorexia

Loss of appetite is common and may be related to tumor effects, pain, or treatment.

Less common, can be a late symptom
Nausea and vomiting

May be caused by gastric outlet obstruction from a pancreatic head tumor, or as a side effect of treatments.

Uncommon
Pancreatitis

New-onset pancreatitis can be the first manifestation of a pancreatic tumor obstructing the pancreatic duct.

Common with jaundice
Pruritus

Generalized itching due to bile salt deposition in the skin from obstructive jaundice.

Signs

Common with obstructive jaundice
Jaundice

Yellow discoloration of skin and sclera.

Variable, more common in pancreatic head tumors
Palpable gallbladder (Courvoisier sign)

A non-tender, distended gallbladder palpable in the right upper quadrant, indicative of distal bile duct obstruction.

Uncommon at presentation, more common in advanced disease
Ascites

Fluid accumulation in the abdomen, indicating peritoneal dissemination or portal hypertension.

Common in advanced disease
Cachexia

Severe weight loss and muscle wasting.

Red FlagsClick to collapse

InvestigationsClick to collapse

Diagnostic

Pancreatic protocol CT (multiphase)

Gold standard initial imaging for diagnosis and staging. Provides detailed assessment of tumor size, location, and relationship to vasculature.

Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA)

Preferred method for tissue diagnosis. Allows for high-yield biopsy and assessment of local lymph nodes.

MRI/MRCP

Alternative to CT for staging, especially for evaluating indeterminate liver lesions or in patients with contrast allergy.

ERCP with stent placement

Therapeutic for biliary decompression in jaundiced patients, not primarily diagnostic.

CT-guided percutaneous biopsy

Alternative when EUS is not feasible or for metastatic lesions (e.g., liver).

Staging

Pancreatic protocol CT of abdomen

Primary tool for assessing local tumor extent and resectability.

Chest/abdomen/pelvis CT with contrast

Complete staging to detect distant metastases (lungs, liver, peritoneum).

PET/CT or PET/MRI

May detect occult metastases not seen on CT, especially in high-risk features (elevated CA 19-9, equivocal findings).

Diagnostic staging laparoscopy

Detects small peritoneal or liver metastases missed on imaging.

EUS

Complementary to CT for assessing vascular involvement and lymph nodes, but not a routine staging tool.

Biomarkers

CA 19-9

Most validated serum biomarker for diagnosis, prognosis, and monitoring response to therapy.

CEA and CA-125

May be considered in patients who are non-secreting for CA 19-9 (Lewis antigen negative).

Genetic testing for inherited mutations (e.g., BRCA1/2, PALB2)

Identifies hereditary cancer syndromes, impacts treatment (e.g., platinum sensitivity), and enables family counseling.

Tumor somatic molecular profiling (NGS)

Identifies actionable alterations (e.g., NTRK, BRAF, MSI, HER2, KRAS G12C) for targeted therapy.

hENT1 expression (IHC)

Potential predictive biomarker for gemcitabine benefit in adjuvant setting.

StagingClick to collapse

AJCC 8th Edition (2017) TNM Staging System

T Categories

StageDescription
TXPrimary tumor cannot be assessed
T0No evidence of primary tumor
TisCarcinoma in situ (includes high-grade PanIN-3, IPMN with high-grade dysplasia, MCN with high-grade dysplasia)
T1Tumor ≀2 cm in greatest dimension
T1aTumor ≀0.5 cm in greatest dimension
T1bTumor >0.5 cm and <1 cm in greatest dimension
T1cTumor 1–2 cm in greatest dimension
T2Tumor >2 cm and ≀4 cm in greatest dimension
T3Tumor >4 cm in greatest dimension
T4Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size

N Categories

StageDescription
NXRegional lymph nodes cannot be assessed
N0No regional lymph node metastases
N1Metastasis in 1–3 regional lymph nodes
N2Metastasis in β‰₯4 regional lymph nodes

M Categories

StageDescription
M0No distant metastasis
M1Distant metastasis (including non-regional lymph node metastasis)

Stage Groupings

GroupCriteriaClinical MeaningFive Yr SurvivalTreatment Intent
Stage 0Tis N0 M0Carcinoma in situ, excellent prognosis if resected.>90% (if resected)Curative (surgical resection)
Stage IAT1 N0 M0Small, localized tumor without nodal involvement. Potentially curable with surgery.~44%Curative (surgery Β± adjuvant therapy)
Stage IBT2 N0 M0Tumor >2 cm but ≀4 cm, node-negative.~30%Curative (surgery Β± adjuvant therapy)
Stage IIAT3 N0 M0Large tumor (>4 cm), node-negative.~15%Curative (surgery Β± adjuvant therapy)
Stage IIBT1-3 N1 M0Tumor of any size with 1-3 positive lymph nodes.~10%Curative (neoadjuvant/adjuvant therapy + surgery)
Stage IIIT1-3 N2 M0 OR T4 Any N M0Either β‰₯4 positive lymph nodes OR tumor involving major arteries (T4), without distant metastases. Often considered locally advanced/unresectable.~5%Primarily palliative (chemotherapy Β± chemoradiation). Surgery considered only in selected cases after neoadjuvant therapy.
Stage IVAny T, Any N, M1Distant metastases present. Incurable.<3%Palliative (systemic therapy, supportive care)

Staging Pearls

  • T4 definition is based on arterial involvement (celiac axis, SMA, CHA), not size or venous involvement. This often defines locally advanced disease.
  • N2 disease (β‰₯4 nodes) is a poor prognostic factor and often indicates need for aggressive systemic therapy.
  • Positive peritoneal cytology is considered M1 disease.
  • Resectability status (resectable, borderline resectable, locally advanced) is determined by CT and is crucial for treatment planning, often superseding AJCC stage in clinical decision-making [PANC-C].
  • After neoadjuvant therapy, restaging CT may not accurately reflect pathologic response; surgery should still be considered if no progression.
  • Adequate lymph node assessment (β‰₯12 nodes) is recommended for accurate staging [PANC-F].

Management PrinciplesClick to collapse

Decisions about diagnosis, resectability, and management of pancreatic cancer should involve multidisciplinary consultation at high-volume centers using appropriate imaging studies [INTRO]. The Panel unanimously endorses participation in clinical trials over standard or accepted therapy [INTRO]. Systemic therapy is used in all stages of pancreatic cancer, including neoadjuvant therapy (resectable or borderline resectable), adjuvant therapy, and first-line or subsequent therapy for locally advanced, metastatic, and recurrent disease [PANC-G]. Goals of systemic therapy should be discussed with patients prior to initiation of therapy, and enrollment in a clinical trial is strongly encouraged [PANC-G]. Less common variants, such as squamous/adenosquamous carcinomas, are treated similarly to adenocarcinoma. There are insufficient data supporting the efficacy of any of the recommended regimens for these rare subtypes. For mixed histologies, the Panel recommends treating the more aggressive histology [PANC-G, PANC-9A footnote nn]. An FDA-approved biosimilar is an appropriate substitute for any recommended systemic biologic therapy in the NCCN Guidelines [PANC-G]. Resections should be done at institutions that perform at least 15–20 pancreatic resections annually [PANC-A 1 of 8].

Curative (resectable disease)

Patients with resectable disease without metastases

Surgery in absence of high-risk features (without neoadjuvant therapy) or neoadjuvant therapy with or without high-risk features followed by surgery [PANC-2]. For resectable disease, upfront surgery remains an option for patients without high-risk features, though neoadjuvant therapy may also be considered [MS-12].

Curative (borderline resectable disease)

Patients with borderline resectable disease and no metastatic disease

Neoadjuvant therapy followed by restaging and resection in patients without disease progression that precludes surgery. Upfront resection in patients with borderline resectable disease is no longer recommended [MS-13]. Neoadjuvant therapy is preferred at or coordinated through a high-volume center [PANC-2A footnote n].

Palliative (locally advanced disease)

Patients with locally advanced disease with good or intermediate PS

Systemic therapy or induction chemotherapy (preferably 4–6 months) followed by chemoradiation or SBRT in selected patients without systemic metastases. Chemoradiation or SBRT alone in patients who are not candidates for induction chemotherapy [PANC-10].

Palliative (metastatic disease)

Patients with metastatic disease and good or intermediate PS

Systemic therapy, potentially with maintenance therapy after response/stable disease, or metastasis-directed therapy at a high-volume center for selected oligometastatic patients [PANC-11]. For poor PS (ECOG 3), palliative and best supportive care with consideration of single-agent chemotherapy or palliative RT [PANC-G 6 of 13].

Palliative (recurrent disease)

Patients with recurrence after resection

Clinical trial preferred, or systemic therapy Β± chemoradiation or SBRT if not previously done. For local recurrence in select patients, surgical re-resection may be considered after detailed restaging assessment and formulation of a multimodal therapy care plan [PANC-6, PANC-6A footnote ii].

Multidisciplinary review should consider involving expertise from diagnostic imaging, interventional endoscopy, medical oncology, radiation oncology, surgery, pathology, geriatric medicine, genetic counseling, and palliative care. Consider consultation with a registered dietitian [PANC-1A footnote b, PANC-6 footnote b]. All recommendations are category 2A unless otherwise indicated [PANC-1].

Mdt Requirements

Good PS is defined as ECOG 0–1 with good biliary drainage and adequate nutritional intake, intermediate PS is defined as ECOG 2, and poor PS is defined as ECOG 3. Patients with ECOG 4 should be exclusively supported by palliative and best supportive care [PANC-10A footnote oo, PANC-11 footnote oo, PANC-12 footnote oo, PANC-G 3 of 13 footnote e].

Performance Status Guide

Management PathwaysClick to collapse

Resectable Disease

Branching: resectability status, high-risk features, patient fitness, molecular profiling

No arterial tumor contact (celiac axis, SMA, or CHA); no tumor contact with SMV/PV or ≀180Β° contact without contour irregularity [PANC-C]
Surgery in absence of high-risk features (without neoadjuvant therapy) (option); Neoadjuvant therapy with or without high-risk features followed by surgery (option)
For patients who did not receive prior neoadjuvant therapy: Capecitabine/Gemcitabine (category 1), modified FOLFIRINOX (category 1) are preferred [PANC-G 2 of 13]. For patients who received prior neoadjuvant therapy, adjuvant options depend on response to neoadjuvant therapy and other clinical considerations. Total duration of systemic therapy is typically 6 months [PANC-5A footnote dd].
Medically inoperable patient with resectable disease by imaging
Treat as locally advanced disease (preferred)
Borderline Resectable Disease, No Metastases

Branching: biopsy status, resectability status, treatment response, molecular profiling

Biopsy positive for adenocarcinoma, borderline resectable by imaging criteria [PANC-C]. Pancreatic head/uncinate: solid tumor contact with CHA without extension to CA or hepatic artery bifurcation; solid tumor contact with SMA ≀180Β°. Pancreatic body/tail: solid tumor contact with CA ≀180Β°. Venous: solid tumor contact with SMV or PV >180Β°, or ≀180Β° with contour irregularity or thrombosis [PANC-C]
Neoadjuvant therapy (preferred)
After neoadjuvant therapy and successful resection, adjuvant therapy may be considered based on response to neoadjuvant therapy and clinical factors [PANC-5A footnote dd].
Biopsy negative or cancer not confirmed
Repeat biopsy (EUS-guided preferred) (preferred)
Treatment Response Following Neoadjuvant Therapy

Branching: radiologic response, CA 19-9 response, metabolic response, clinical improvement

Significant response: significant reduction of tumor size/volume on CT/MRI (RECIST), significant reduction of CA19-9/CEA, and/or significant reduction of PET SUV/metabolic tumor volume [PANC-D Table 1]
Surgical resection recommended (preferred)
Consolidative chemoradiation may be considered after chemotherapy and prior to surgical resection [PANC-D Table 1].
Minimal response: stable or minimal reduction of tumor size/volume, CA19-9, and/or PET SUV [PANC-D Table 1]
Surgical resection considered in select cases (option); Switch to different neoadjuvant therapy (option)
Disease progression not precluding surgery: increase of tumor size/volume or degree of vascular involvement on imaging, increase of CA19-9/CEA, and/or increase of PET SUV, without metastatic progression [PANC-D Table 1, PANC-4 footnote y]
Consider alternate neoadjuvant chemotherapy (preferred)
Disease progression precluding surgery: progression with metastatic disease or local progression precluding resection [PANC-4]
Treat as locally advanced or metastatic disease (preferred)
Postoperative Adjuvant Treatment (No Prior Neoadjuvant Therapy)

Branching: prior neoadjuvant status, pathologic findings, recovery from surgery, PS

No prior neoadjuvant therapy, no evidence of recurrence or metastatic disease after resection [PANC-5]
Additional chemotherapy Β± chemoradiation (preferred)
Preferred: Capecitabine/Gemcitabine (category 1), modified FOLFIRINOX (category 1). Other recommended: Gemcitabine (category 1), Bolus Fluorouracil/Leucovorin (category 1), Continuous infusion Fluorouracil [PANC-G 2 of 13]. If considering chemoradiation, neoadjuvant or adjuvant chemotherapy should be given prior to chemoradiation [PANC-5A footnote bb]. RTOG 0848 showed survival benefit with postoperative RT in node-negative disease receiving single-agent systemic therapy [PANC-5A footnote cc].
Postoperative Adjuvant Treatment (Prior Neoadjuvant Therapy)

Branching: response to neoadjuvant, completeness of systemic therapy, PS

Prior neoadjuvant therapy, no evidence of recurrence or metastatic disease [PANC-5]
Consider additional chemotherapy and/or chemoradiation as clinically indicated (preferred)
Patients who have received neoadjuvant chemoradiation or chemotherapy may be candidates for additional chemotherapy (or chemoradiation if none was delivered neoadjuvantly) following surgery and multidisciplinary review [PANC-5A footnote dd]. Restaging with imaging should be done after each treatment modality if chemotherapy precedes chemoradiation [PANC-5A footnote z].
Recurrence After Resection β€” Local Recurrence

Branching: recurrence pattern, PS, molecular profiling, prior therapy

Local recurrence isolated to pancreatic bed, pancreatic remnant, or mesenteric root [PANC-6, PANC-E 2 of 3]
Surgical consultation and multidisciplinary review for select patients (option); Systemic therapy Β± chemoradiation or SBRT (option)
Metastatic Recurrent Disease Following Surgery

Branching: time from completion of primary therapy, prior therapy, PS

β‰₯6 months from completion of primary therapy [PANC-7, PANC-G 9 of 13 footnote q]
Repeat previously administered systemic therapy or alternate systemic therapy (option)
<6 months from completion of primary therapy [PANC-7, PANC-G 9 of 13 footnote q]
Switch to different drug class or alternate systemic therapy (preferred)
Indolent/oligometastatic disease in rare circumstances [PANC-7 footnote jj, PANC-12 footnote jj]
Refer to high-volume center for possible metastasis-directed therapy (useful_in_certain_circumstances)
Locally Advanced Disease

Branching: PS, disease progression, molecular profiling

Good or intermediate PS (ECOG 0–2), locally advanced disease (solid tumor contact >180Β° with SMA or CA, or not currently amenable to resection due to complete SMV/PV occlusion) [PANC-C, PANC-10]
Systemic therapy (preferred); Chemoradiation or SBRT (useful_in_certain_circumstances)
Poor PS (ECOG 3) [PANC-10, PANC-G 4 of 13]
Palliative and best supportive care (preferred); Single-agent chemotherapy (other_recommended)
Disease progression after initial therapy, good or intermediate PS maintained [PANC-10]
Clinical trial preferred or systemic therapy (preferred); Chemoradiation or SBRT (useful_in_certain_circumstances)
Metastatic Disease β€” First-Line Therapy

Branching: PS, BRCA1/2 or PALB2 mutation status, molecular profiling (BRAF, NTRK, MSI-H, RET, KRAS G12C, HER2, NRG1, FGFR)

Good PS (ECOG 0–1), metastatic disease, no known actionable mutations [PANC-11, PANC-G 5 of 13]
Preferred systemic therapy (preferred); Other recommended regimens (other_recommended)
Good PS, known BRCA1/2 or PALB2 mutation [PANC-G 5 of 13]
Platinum-based therapy preferred (preferred)
Intermediate PS (ECOG 2), metastatic disease [PANC-G 6 of 13]
Preferred regimens (preferred)
Poor PS (ECOG 3), metastatic disease [PANC-G 6 of 13]
Palliative and best supportive care (preferred); Single-agent chemotherapy (other_recommended)
BRAF V600E mutation-positive, any PS [PANC-G 5 of 13, PANC-G 6 of 13]
Dabrafenib/Trametinib (useful_in_certain_circumstances)
NTRK gene fusion-positive [PANC-G 5 of 13, PANC-G 6 of 13]
Entrectinib, Larotrectinib, or Repotrectinib (useful_in_certain_circumstances)
MSI-H, dMMR, or TMB-H (β‰₯10 mut/Mb) [PANC-G 5 of 13, PANC-G 6 of 13]
Pembrolizumab (useful_in_certain_circumstances)
RET gene fusion-positive [PANC-G 5 of 13, PANC-G 6 of 13]
Selpercatinib (useful_in_certain_circumstances)
Metastatic Disease β€” Maintenance Therapy (Good/Intermediate PS)

Branching: disease status after 4-6 months, prior platinum-based therapy, BRCA/PALB2 mutation status

No disease progression after at least 4–6 months of chemotherapy, assuming acceptable tolerance [PANC-11, PANC-G 7 of 13]
Maintenance therapy options (preferred); Other maintenance options (other_recommended); Β± Metastasis-directed therapy (useful_in_certain_circumstances)
Metastatic Disease β€” Subsequent Therapy

Branching: PS, prior therapy type, molecular profiling, dMMR/MSI status, HER2 status, KRAS G12C, NRG1 fusion

Good PS (ECOG 0–1), prior gemcitabine-based therapy [PANC-G 8 of 13]
Preferred subsequent therapy (preferred)
Good PS, prior fluoropyrimidine-based therapy [PANC-G 8 of 13]
Useful in certain circumstances (useful_in_certain_circumstances)
Intermediate PS (ECOG 2), prior fluoropyrimidine-based therapy [PANC-G 9 of 13]
Preferred subsequent therapy (preferred)
Intermediate PS, prior gemcitabine-based therapy [PANC-G 9 of 13]
Preferred subsequent therapy (preferred)
Poor PS (ECOG 3), prior fluoropyrimidine-based therapy [PANC-G 10 of 13]
Palliative and best supportive care (preferred); Gemcitabine (other_recommended)
KRAS G12C mutation-positive, any PS [PANC-G 8 of 13, PANC-G 9 of 13, PANC-G 10 of 13]
Adagrasib or Sotorasib (useful_in_certain_circumstances)
HER2-positive (IHC3+ or IHC2+ with FISH HER2 amplified), good PS [PANC-G 8 of 13]
Fam-trastuzumab deruxtecan-nxki (useful_in_certain_circumstances)
NRG1 gene fusion-positive [PANC-G 8 of 13, PANC-G 9 of 13]
Zenocutuzumab-zbco (useful_in_certain_circumstances)
MSI-H or dMMR, no prior immunotherapy [PANC-G 8 of 13, PANC-G 9 of 13, PANC-G 10 of 13]
Dostarlimab-gxly or Pembrolizumab (useful_in_certain_circumstances)
TMB-H (β‰₯10 mut/Mb), no prior immunotherapy, good or intermediate PS [PANC-G 8 of 13, PANC-G 9 of 13]
Ipilimumab + Nivolumab (useful_in_certain_circumstances)

Pretreatment EvaluationClick to collapse

Initial Imaging
Pancreatic protocol CT or MRI of abdomen (preferred CT; MRI acceptable as alternative) [PANC-1, PANC-A 1 of 8]
Category 2A. High-quality dedicated imaging of the pancreas should be performed at presentation, preferably within 4 weeks of surgery, and following neoadjuvant treatment [PANC-A 1 of 8]. Multidetector CT angiography with thin sub-millimeter axial sections using dual-phase pancreatic protocol is preferred [PANC-A 1 of 8].
Chest and pelvis CT with contrast [PANC-1, PANC-A 1 of 8]
Category 2A. Imaging with contrast as appropriate for disease management unless contraindicated [PANC-1A footnote c].
Consider endoscopic ultrasonography (EUS) [PANC-1, PANC-A 2 of 8]
Category 2A. EUS to confirm primary site of involvement; EUS-guided biopsy if clinically indicated [PANC-1A footnote d]. Not recommended as a routine staging tool but may be complementary to CT [PANC-A 2 of 8].
Consider MRI as clinically indicated for indeterminate liver lesions [PANC-1]
Category 2A.
Consider PET/CT or PET/MRI in patients with high-risk features [PANC-1, PANC-A 2 of 8]
Category 2A. May be considered after formal pancreatic CT protocol to detect extra-pancreatic metastases. Not a substitute for high-quality contrast-enhanced CT [PANC-1A footnote e, PANC-A 2 of 8]. For neoadjuvant therapy, consider PET/CT or PET/MRI before and after initiation [PANC-A 2 of 8].
Consider ERCP with stent placement if jaundice present [PANC-1]
Category 2A [PANC-1A footnote f].
Consider staging laparoscopy as clinically indicated [PANC-2, PANC-3, PANC-9 footnote w]
Category 2A. Especially in select cases with high risk for metastatic disease [PANC-2A footnote r, PANC-4A footnote w].
Laboratory Studies
CA 19-9 after adequate biliary drainage [PANC-1, PANC-A 2 of 8]
Category 2A. Elevated CA 19-9 does not necessarily indicate cancer or advanced disease. May be elevated due to biliary obstruction, infection, or inflammation. Undetectable in Lewis antigen-negative individuals [PANC-1A footnote g]. Consider obtaining CEA and CA-125 in patients who are nonsecreting or those with normal CA 19-9 levels [PANC-1A footnote g].
Liver function tests and baseline [PANC-1]
Category 2A.
Pathologic Confirmation
Biopsy confirmation [PANC-1]
Category 2A. Core biopsy recommended, if possible, to obtain adequate tissue for molecular profiling or other ancillary studies [PANC-1A footnote i]. Biopsy proof of malignancy is not required before surgical resection when clinical suspicion is high and a non-diagnostic biopsy should not delay surgical resection [MS-10].
EUS-guided biopsy preferred for tissue acquisition [PANC-B]
Category 2A. Preferably a latest generation ('core') EUS needle should be used [PANC-B]. EUS-guided biopsy is preferable to CT-guided biopsy in patients with non-metastatic disease [PANC-A 2 of 8].
Molecular Profiling and Genetic Testing
Tumor/somatic molecular profiling using NGS assay [PANC-1, PANC-5, PANC-6, PANC-7, PANC-8, PANC-9]
Category 2A. Recommended for ALL patients who are candidates for anti-cancer therapy. Should identify clinically actionable alterations including fusions (ALK, NRG1, NTRK, ROS1, FGFR2, RET), mutations (BRAF, BRCA1/2, KRAS, PALB2), amplifications (HER2), MSI, dMMR, TMB via FDA-approved/validated NGS-based assay. RNA sequencing recommended in addition to DNA sequencing for better detection of gene fusions. HER2 overexpression via IHC Β± FISH also recommended. Testing on tumor tissue preferred; ctDNA testing can be considered if tissue testing not feasible [PANC-1A footnote j, PANC-5A footnote j].
Genetic testing for inherited mutations [PANC-1, PANC-2, PANC-5, PANC-6, PANC-7, PANC-8, PANC-9]
Category 2A. Recommended for any patient with confirmed pancreatic cancer using comprehensive gene panels for hereditary cancer syndromes. Genetic counseling recommended for patients who test positive for pathogenic mutations (ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53) or those with positive family history of cancer, especially pancreatic cancer, regardless of mutation status [PANC-1A footnote h, PANC-2A footnote h].
Assessment of Jaundice/Biliary Drainage
ERCP with stent placement for biliary obstruction [PANC-1, PANC-B]
Category 2A. Biliary drainage is not routinely recommended prior to planned upfront surgery. Consider for: symptoms of cholangitis/fever, severe symptomatic jaundice (intense pruritus), or if surgery delayed for any reason including neoadjuvant therapy [PANC-B]. SEMS preferred over plastic stents. Fully covered SEMS should be considered if tissue diagnosis not certain [PANC-B].
Performance Status and Geriatric Assessment
Performance status evaluation (ECOG) [PANC-G 3 of 13 footnote e]
Category 2A. Good PS: ECOG 0–1 with good biliary drainage and adequate nutritional intake. Intermediate PS: ECOG 2. Poor PS: ECOG 3. ECOG 4: exclusively palliative and best supportive care [PANC-G 3 of 13 footnote e].
Consider evaluational geriatric assessment for older adults [PANC-G 4 of 13, PANC-G 5 of 13, PANC-G 6 of 13]
Category 2A. See NCCN Guidelines for Older Adult Oncology [PANC-G 4 of 13].
Nutritional Assessment
Nutritional evaluation with registered dietitian [PANC-1A footnote b]
Category 2A. Consider consultation with a registered dietitian [PANC-1A footnote b, PANC-I 2 of 2 footnote g].

SurgeryClick to collapse

Surgical resection is the only potentially curative technique for managing pancreatic cancer. The goals of surgery include an oncologic resection of the primary tumor and regional lymph nodes. Careful intraoperative staging should rule out peritoneal, liver, and distant lymph node metastases, and resection should only be done in the absence of distant disease [PANC-E 1 of 3, MS-16]. Resections should be done at institutions that perform at least 15–20 pancreatic resections annually [PANC-A 1 of 8].

Surgical Role

Achievement of an R0 resection is the primary goal, as margin-positive specimens are associated with poor long-term survival [PANC-E 1 of 3, references 1,2].

Consider frozen section analysis of the pancreatic neck and bile duct. Avoid cautery at margins sent for frozen section. If tumor located within 5 mm of margins, consider further excision to ensure at least 5 mm of clearance [PANC-E 1 of 3].

Medial dissection of pancreatic head lesions is best achieved by complete mobilization of PV and SMV from uncinate process. Skeletalization of lateral, posterior, and anterior borders of SMA down to adventitia maximizes uncinate yield and radial margin [PANC-E 1 of 3, references 3,4].

Differentiation of tumor infiltration into vein wall from tumor-related desmoplasia is frequently impossible. Liberal use of partial or complete vein excision when tumor infiltration is suspected is supported by data [PANC-E 1 of 3].

Positive cytology from washings obtained at laparoscopy or laparotomy is equivalent to M1 disease [PANC-A 2 of 8].

Spleen preservation is not indicated in adenocarcinoma [PANC-E 2 of 3].

For pancreas neck adenocarcomas, depending on extent of involvement, extended pancreaticoduodenectomy, extended distal pancreatectomy, or total pancreatectomy may be required [PANC-E 2 of 3, references 10,11].

There is a potential benefit of re-resection for recurrences in selected patients after careful multidisciplinary evaluation with detailed restaging assessment and multimodal therapy care plan [PANC-6A footnote ii, PANC-E 2 of 3].

Procedures

Pancreatoduodenectomy (Whipple Procedure)

Adenocarcinomas of the pancreatic head and uncinate process [PANC-E 1 of 3].

Distal Pancreatectomy with En Bloc Splenectomy

Adenocarcinomas of the pancreatic body and tail [PANC-E 2 of 3].

Total Pancreatectomy

May be required when tumor diffusely involves the pancreas, is present at multiple sites, or for pancreas neck adenocarcinomas to achieve R0 resection [MS-19, PANC-E 2 of 3].

Staging Laparoscopy

Diagnostic staging to rule out metastases not detected on imaging, especially for body and tail lesions, or in patients with high-risk features [PANC-A 2 of 8]. Can be performed at time of original diagnosis and following neoadjuvant chemotherapy.

Biliary-Enteric Bypass (Open)

For patients found to have unresectable disease at surgery who present with jaundice. Provides durable palliation [PANC-8, MS-48].

Radiation TherapyClick to collapse

Radiation is used in five clinical scenarios: resectable/borderline resectable (neoadjuvant setting), resected (adjuvant), locally advanced, palliative, and recurrent disease [PANC-H 1 of 7]. Goals include sterilizing vessel margins, enhancing likelihood of margin-negative resection, providing adequate local control to prevent/delay progression, and palliating pain, bleeding, or obstructive symptoms [PANC-H 1 of 7]. Based on LAP-07 trial data, there is no clear survival benefit with addition of conventional chemoradiation following gemcitabine monotherapy; however, chemoradiation may improve local control and delay the need for resumption therapy [PANC-G 3 of 13 footnote i, reference Hammel P, et al. JAMA 2016;315:1844-1853].

Principles

  • Patients are best cared for by a multidisciplinary team [PANC-H 1 of 7].
  • Prior to initiation of RT, staging is optimally determined with contrast-enhanced abdominal CT and/or MRI [PANC-H 1 of 7].
  • IMRT is preferred over 3D-CRT for conventional or hypofractionated RT, particularly if dose escalation is considered [PANC-H 2 of 7].
  • A motion management strategy should be considered, including 4D-CT, respiratory gating, breath-hold, respiratory tracking, or abdominal compression [PANC-H 2 of 7].
  • The role and definition of elective target volume irradiation remain unclear, but emerging data suggest value to elective targeting of at-risk anatomic sites (Triangle Volume) and/or regional nodal basins. More prospective data needed [PANC-H 2 of 7, reference 6].
  • Fiducial markers (1–5, preferably β‰₯3) placed under EUS may be useful for targeting [PANC-H 2 of 7].
  • SBRT should be delivered at experienced, high-volume center with image-guided RT technology or in clinical trial [PANC-H 4 of 7 footnote c].
  • SBRT should be avoided if direct invasion of bowel or stomach is observed [PANC-H 4 of 7 footnote d].

Dose Frameworks

NameTotal DoseDose Per FractionFractionsScheduleIndication
Neoadjuvant/Definitive Chemoradiation36–56 Gy1.8–2.4 Gy20–30Daily fractionation, 5 days per weekResectable/borderline resectable (neoadjuvant), locally advanced disease, recurrent disease [PANC-H 3 of 7, PANC-H 4 of 7]
Adjuvant Chemoradiation45–50.4 Gy1.8–2.0 Gy25–28Daily fractionation, 5 days per weekPost-resection with positive margins or high-risk features [PANC-H 3 of 7]
SBRT (3-fraction)30–45 Gy10–15 Gy3Per institutional protocolLocally advanced, recurrent, or select borderline resectable disease [PANC-H 4 of 7]
SBRT (5-fraction)25–50 Gy5–10 Gy5Per institutional protocolLocally advanced, recurrent, or select borderline resectable disease [PANC-H 4 of 7]
SBRT (hypofractionated, protracted)67.5–75 Gy4.5–3 Gy15–25Per institutional protocolLocally advanced disease; caution with higher doses; normal tissue constraints must be respected [PANC-H 4 of 7]
Palliative RTVariableVariableVariableBased on burden of disease, normal tissue tolerance, and expected survivalPain, bleeding, obstructive symptoms in metastatic or non-metastatic disease [PANC-H 5 of 7]
Single Fraction SBRT (Celiac Plexus)VariableSingle fraction1Single treatmentCeliac axis pain relief [PANC-H 5 of 7, reference Lawrence YR, et al. Lancet Oncol 2024;25:1070-1079]

Approaches

NameDose FractionationConcurrent ChemotherapyIndicationKey TrialToxicities
Neoadjuvant Chemoradiation (Resectable/Borderline Resectable)36 Gy in 2.4 Gy fractions to 45–54 Gy in 1.8–2.0 Gy fractions (doses higher than 54 Gy may be considered in clinical trial) [PANC-H 3 of 7]Capecitabine with concurrent RT or Continuous infusion Fluorouracil with concurrent RT (preferred); Gemcitabine with concurrent RT (other recommended) [PANC-G 11 of 13]Neoadjuvant setting for resectable/borderline resectable disease. Consolidative chemoradiation sometimes included following neoadjuvant chemotherapy [PANC-H 3 of 7, PANC-G 1 of 13].PREOPANC (Versteijne E, et al. J Clin Oncol 2020;38:1763-1773); Alliance A021101 (Katz MH, et al. JAMA Surg 2016;151:e161137)GI toxicities including nausea, vomiting, diarrhea; hematologic toxicities. IMRT may reduce grade 3/4 GI toxicities compared to 3D-CRT [PANC-H 6 of 7, reference 502]
Adjuvant Chemoradiation45–50.4 Gy in 1.8–2.0 Gy fractions (25–28 fx) to tumor bed, surgical anastomoses, and adjacent lymph node basins [PANC-H 3 of 7]Capecitabine with concurrent RT or Continuous infusion Fluorouracil with concurrent RT (preferred); Gemcitabine with concurrent RT (other recommended) [PANC-G 11 of 13]Post-resection for patients with positive resection margins or other high-risk features; primarily in node-negative disease based on RTOG 0848 [PANC-5A footnote cc, PANC-H 3 of 7]RTOG 0848 (Abrams RA, et al. J Clin Oncol 2024;42(16 Suppl):Abstract 4005) showed survival benefit with postoperative RT in node-negative disease receiving single-agent systemic therapyGI toxicities, hematologic toxicities; normal tissue constraints for stomach, duodenum, liver, kidneys, spinal cord [PANC-H 5 of 7]
Induction Chemotherapy Followed by Chemoradiation or SBRT (Locally Advanced)45–56 Gy in 1.8–2.2 Gy fractions for chemoradiation; SBRT 3–5 fractions [PANC-H 4 of 7]Fluoropyrimidine-based concurrent chemotherapy for chemoradiation [PANC-H 4 of 7]Locally advanced disease without systemic metastases in patients with good/intermediate PS. Induction chemotherapy (preferably 4–6 months) followed by consolidation chemoradiation [PANC-10, PANC-H 4 of 7]LAP-07 (Hammel P, et al. JAMA 2016;315:1844-1853) showed no clear survival benefit but may improve local control; SCALOP (Mukherjee S, et al. Lancet Oncol 2013;14:317-326) favored capecitabine-based chemoradiationSimilar to above; SBRT may result in less severe radiation-induced lymphopenia compared to conventional chemoradiation [MS-47, reference 451]
Upfront Chemoradiation or SBRT (Locally Advanced)45–56 Gy in 1.8–2.2 Gy fractions for chemoradiation; SBRT 3–5 fractions [PANC-H 4 of 7]Fluoropyrimidine-based [PANC-H 4 of 7]Patients not candidates for induction chemotherapy, or presenting with poorly controlled pain or local obstructive symptoms [PANC-10, PANC-H 4 of 7, PANC-G 3 of 13 footnote j]ECOG-4201 (Loehrer PJ, et al. J Clin Oncol 2011;29:4105-4112) showed OS benefit for chemoradiation vs chemotherapy alone but limited by poor accrualGI toxicities, hematologic toxicities
Chemoradiation or SBRT for Recurrent Disease45–56 Gy in 1.8–2.2 Gy fractions for chemoradiation; SBRT 3–5 fractions [PANC-H 4 of 7]Fluoropyrimidine-based for chemoradiation [PANC-H 4 of 7]Local recurrence in the pancreatic bed if not previously performed; only if primary site is sole site of progression [PANC-6, PANC-H 4 of 7]Limited data specific to recurrent disease settingGI toxicities; must respect normal tissue constraints given prior treatment [PANC-H 4 of 7]
Palliative Radiation TherapyVariable; short course for painful bony metastases; single fraction SBRT for celiac axis pain [PANC-H 5 of 7]With or without concurrent chemotherapy [PANC-H 5 of 7]Pain, bleeding, obstructive symptoms in metastatic or non-metastatic disease; osseous pain from bone metastases [PANC-H 5 of 7]Lawrence YR, et al. Lancet Oncol 2024;25:1070-1079 (celiac plexus radiosurgery for pain management)Should take into account burden of disease, normal tissue tolerance, and expected survival [PANC-H 5 of 7]

Systemic TherapyClick to collapse

Systemic therapy is used in all stages of pancreatic cancer including neoadjuvant therapy (resectable/borderline resectable), adjuvant therapy, and first-line or subsequent therapy for locally advanced, metastatic, and recurrent disease [PANC-G]. Consider testing for actionable somatic findings including fusions (ALK, NRG1, NTRK, ROS1, FGFR2, RET), mutations (BRAF, BRCA1/2, KRAS, PALB2), amplifications (HER2), MSI, dMMR, TMB using FDA-approved/validated NGS-based assay, and HER2 overexpression via IHC Β± FISH [PANC-G]. If BRCA1/2 status is unknown, treat with systemic therapy as clinically indicated [PANC-G]. For information regarding DPYD testing, see NCCN Guidelines for Colon Cancer [PANC-G]. Pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection may be substituted for IV Pembrolizumab with different dosing and administration instructions [PANC-G].

Neoadjuvant (Resectable/Borderline Resectable)
Limited evidence to recommend specific neoadjuvant regimens off-study. Practices vary regarding use of chemotherapy and radiation. Consolidative chemoradiation sometimes included. Most NCCN Member Institutions prefer neoadjuvant therapy at or coordinated through high-volume center [PANC-G 1 of 13, PANC-2A footnote n]. PAXG showed improved EFS compared to mFOLFIRINOX in resectable/borderline resectable disease (median EFS 16.0 vs 10.2 months; HR 0.63; P=.0018) but listed as useful in certain circumstances due to limited institutional experience [PANC-G 1 of 13, reference 2].
Preferred: Albumin-bound Paclitaxel/Gemcitabine; FOLFIRINOX or modified FOLFIRINOX (limited to ECOG 0–1); Cisplatin/Gemcitabine (only for known BRCA1/2 or PALB2 mutations, β‰₯2 to 6 cycles) [PANC-G 1 of 13]
Adjuvant (No Prior Neoadjuvant Therapy)
ESPAC-4: Gemcitabine/Capecitabine superior to Gemcitabine alone (HR 0.82; 95% CI 0.68–0.98; P=.032; median OS 28.0 vs 25.5 months) [reference 5]. PRODIGE 24/CCTG PA.6: mFOLFIRINOX superior to Gemcitabine (5-year DFS 26.1% vs 19.0%; median OS 53.5 vs 35.5 months) [reference 1].
Preferred: Capecitabine/Gemcitabine (category 1); Modified FOLFIRINOX (category 1, limited to ECOG 0–1) [PANC-G 2 of 13]
Locally Advanced Disease (First-Line, Good PS 0–1)
Albumin-bound Paclitaxel/Gemcitabine and FOLFIRINOX/mFOLFIRINOX recommendations based on extrapolations from randomized trials in metastatic disease [PANC-G 3 of 13 footnote f]. NALIRIFOX: high-level evidence over Albumin-bound Paclitaxel/Gemcitabine, but does not appear to have advantage over FOLFIRINOX [PANC-G 3 of 13 footnote g].
Preferred: Albumin-bound Paclitaxel/Gemcitabine; FOLFIRINOX or modified FOLFIRINOX (ECOG 0–1); NALIRIFOX; Cisplatin/Gemcitabine or FOLFIRINOX/mFOLFIRINOX (only for known BRCA1/2 or PALB2 mutations) [PANC-G 3 of 13]
Locally Advanced Disease (First-Line, Intermediate PS 2)
Reduced intensity regimens appropriate for intermediate PS [PANC-G 4 of 13]
Preferred: Albumin-bound Paclitaxel/Gemcitabine; Capecitabine; Gemcitabine [PANC-G 4 of 13]
Locally Advanced Disease (First-Line, Poor PS 3)
Single-agent therapy for poor PS; marginal benefit from systemic therapy [PANC-G 4 of 13 footnote l]
Preferred: Gemcitabine 1000 mg/m2 over 30 minutes, weekly for 3 weeks every 28 days (category 1) [PANC-G 4 of 13]
Metastatic Disease (First-Line, Good PS 0–1)
MPACT: Albumin-bound Paclitaxel/Gemcitabine improved OS vs Gemcitabine alone (8.5 vs 6.7 months; P<.001; HR 0.72) [reference 7]. FOLFIRINOX: OS 11.1 vs 6.8 months (P<.001) [reference 8]. NALIRIFOX: NAPOLI-3 showed significant OS and PFS improvement over Albumin-bound Paclitaxel/Gemcitabine (reference 9).
Preferred: Albumin-bound Paclitaxel/Gemcitabine (category 1); FOLFIRINOX (category 1); NALIRIFOX (category 1); Modified FOLFIRINOX [PANC-G 5 of 13]
Metastatic Disease (First-Line, Intermediate PS 2)
Reduced intensity options appropriate for intermediate PS [PANC-G 6 of 13]
Preferred: Albumin-bound Paclitaxel/Gemcitabine (category 1); Capecitabine; CAPEOX; FOLFIRI; FOLFOX; Gemcitabine [PANC-G 6 of 13]
Metastatic Disease (First-Line, Poor PS 3)
Evidence suggests marginal benefit from systemic therapy in poor PS [PANC-G 6 of 13 footnote l]
Preferred: Palliative and best supportive care [PANC-G 6 of 13]
Metastatic Disease (Maintenance, Good/Intermediate PS, Prior Platinum with Germline BRCA1/2)
POLO trial: Olaparib vs placebo PFS 7.4 vs 3.8 months (P=.004) [reference 435]. No OS difference at interim analysis [PANC-G 7 of 13].
Preferred: Olaparib [PANC-G 7 of 13]
Subsequent Therapy (Locally Advanced/Metastatic, Good PS 0–1, Prior Gemcitabine)
NAPOLI-1: Nanoliposomal irinotecan + FU/LV improved PFS (3.1 vs 1.5 months; HR 0.56; P<.001) and OS (6.2 vs 4.2 months; HR 0.75; P=.042) vs FU/LV alone [reference 32]. CONKO-003: OFF improved OS vs FU/LV (5.9 vs 3.3 months; HR 0.66; P=.01) [reference 400].
Preferred: Fluorouracil/Leucovorin/Liposomal Irinotecan (category 1 for metastatic disease); Capecitabine; CAPEOX; Continuous infusion Fluorouracil; Bolus Fluorouracil/Leucovorin; FOLFIRI; FOLFIRINOX or modified FOLFIRINOX; FOLFOX; OFF [PANC-G 8 of 13]
Subsequent Therapy (Poor PS 3)
Marginal benefit from systemic therapy in poor PS [PANC-G 10 of 13 footnote l]
Preferred: Palliative and best supportive care [PANC-G 10 of 13]

Key Regimens

Albumin-bound Paclitaxel/Gemcitabine
Albumin-bound Paclitaxel 125 mg/m2 IV Days 1, 8, 15 + Gemcitabine 1000 mg/m2 IV Days 1, 8, 15
FOLFIRINOX
Oxaliplatin 85 mg/m2 IV Day 1 + Irinotecan 180 mg/m2 IV Day 1 + Leucovorin 400 mg/m2 IV Day 1 + Fluorouracil bolus 400 mg/m2 IV Day 1 (often omitted due to toxicity) + Fluorouracil infusion 2400 mg/m2 over 46 hours IV Days 1-2
Modified FOLFIRINOX
Oxaliplatin 85 mg/m2 IV Day 1 + Irinotecan 150 mg/m2 (reduced from 180) IV Day 1 + Leucovorin 400 mg/m2 IV Day 1 + Fluorouracil bolus Omitted or reduced IV Often omitted + Fluorouracil infusion 2400 mg/m2 over 46 hours IV Days 1-2
NALIRIFOX (Liposomal Irinotecan/Fluorouracil/Leucovorin/Oxaliplatin)
Liposomal Irinotecan 50 mg/m2 IV Days 1 and 8 + Oxaliplatin 60 mg/m2 IV Day 1 + Leucovorin 400 mg/m2 IV Day 1 + Fluorouracil 2400 mg/m2 over 46 hours IV Days 1-2
Cisplatin/Gemcitabine (BRCA1/2 or PALB2 only)
Cisplatin 25 mg/m2 IV Days 1, 8, 15 + Gemcitabine 1000 mg/m2 IV Days 1, 8, 15
Gemcitabine Monotherapy
Gemcitabine 1000 mg/m2 IV Days 1, 8, 15 (every 28 days)
Gemcitabine Fixed-Dose-Rate
Gemcitabine 10 mg/m2/min for 100 minutes IV Days 1, 8, 15
Fluorouracil/Leucovorin/Liposomal Irinotecan
Liposomal Irinotecan 70 mg/m2 (or 80 mg/m2 if no prior irinotecan) IV Day 1 + Leucovorin 400 mg/m2 IV Day 1 + Fluorouracil 2400 mg/m2 over 46 hours IV Days 1-2
Erlotinib/Gemcitabine
Erlotinib 100 mg PO Oral Daily + Gemcitabine 1000 mg/m2 IV Days 1, 8, 15
Capecitabine/Gemcitabine
Capecitabine 1660 mg/m2/day Oral Days 1–21 + Gemcitabine 1000 mg/m2 IV Days 1, 8, 15
Olparib (Maintenance, BRCA1/2 germline only)
Olaparib 300 mg PO Oral Twice daily
FOLFOX
Oxaliplatin 85 mg/m2 IV Day 1 + Leucovorin 400 mg/m2 IV Day 1 + Fluorouracil 2400 mg/m2 over 46 hours IV Days 1-2
FOLFIRI
Irinotecan 150–180 mg/m2 IV Day 1 + Leucovorin 400 mg/m2 IV Day 1 + Fluorouracil 2400 mg/m2 over 46 hours IV Days 1-2
Pembrolizumab (MSI-H/dMMR or TMB-H)
Pembrolizumab 200 mg IV Day 1 every 3 weeks (or 400 mg every 6 weeks)
Larotrectinib/Entrectinib (NTRK fusion-positive)
Larotrectinib 100 mg PO Oral Twice daily + Entrectinib 600 mg PO Oral Daily
Dabrafenib/Trametinib (BRAF V600E)
Dabrafenib 150 mg PO Oral Twice daily + Trametinib 2 mg PO Oral Once daily

Treatment Response AssessmentClick to collapse

Title

Treatment Response Assessment in Pancreatic Adenocarcinoma

Timing

Serial imaging as indicated to assess disease response. For neoadjuvant therapy, restaging should include pancreatic protocol CT or MRI of abdomen, chest/pelvis CT, consider PET, post-treatment CA 19-9, and consider staging laparoscopy as clinically indicated [PANC-4, PANC-10 footnote pp]. Surgery is ideally performed 4–8 weeks after neoadjuvant therapy completion, though can be performed >8 weeks (radiation-induced fibrosis may make surgery more difficult) [MS-15]. For locally advanced/metastatic disease, serial CT with contrast (routine single portal venous phase or dedicated pancreatic protocol if surgery still contemplated) or MRI with contrast of known sites of disease to determine therapeutic benefit [PANC-A 2 of 8].

Response Logic

  • Response can be determined by imaging (RECIST criteria) and/or other clinical parameters including change in performance status, pain, satiety, weight/nutritional status, diabetes control [PANC-D, MS-15].

  • For neoadjuvant therapy: four response categories defined β€” significant, minimal, disease progression not precluding surgery, and disease progression precluding surgery [PANC-4, PANC-D Table 1].

  • Disease progression is defined by rising CA 19-9 or enlargement of the mass [PANC-4A footnote y].

  • Retrospective studies suggest imaging characteristics may not be a reliable indicator of resectability after neoadjuvant therapy. Determinations of resectability should be made on individualized basis in multidisciplinary setting [PANC-A 2 of 8, MS-14].

  • Radiographic response does not correlate with pathologic response in borderline resectable disease. If no apparent tumor shrinkage after neoadjuvant treatment and no extrapancreatic progressive disease, surgery should still be attempted [MS-14, references 144,145].

  • In marked radiographic improvement, patient should be referred to high-volume center for consideration of surgery. If radiographic stability with marked clinical improvement or decline in CA 19-9, patient should still be referred [PANC-10 footnote ss].

  • Mixed responses (reduction in tumor size on CT but increase in CA 19-9): third response metric (PET response) and multidisciplinary tumor board discussion may assist in determining category (2 out of 3 metrics) [PANC-D footnote c].

  • Negative predictive value of CA 19-9: low positive predictive value for screening but useful for monitoring treatment response and prognosis in various settings [MS-10-11].

Imaging Recommendations

  • Pancreatic protocol CT or MRI after neoadjuvant therapy for restaging [PANC-4, PANC-A 1 of 8].

  • Chest/pelvis CT with contrast for complete staging [PANC-4, PANC-A 1 of 8].

  • PET/CT or PET/MRI before and after neoadjuvant therapy initiation to assess metabolic response and for restaging [PANC-2A footnote o, PANC-A 2 of 8, PANC-D footnote f].

  • For locally advanced/metastatic disease: serial CT with contrast or MRI with contrast of known sites of disease [PANC-A 2 of 8].

  • In the adjuvant setting: baseline postoperative CT (chest, abdomen, pelvis) with contrast [PANC-5].

  • Radiology reporting template recommended (morphologic, arterial, venous, extrapancreatic evaluation) [PANC-A 5-8 of 8].

Biopsy Or Salvage Logic

  • Biopsy confirmation recommended after neoadjuvant therapy if there is a question about response or if patient is not surgical candidate, to distinguish viable tumor from treatment-related changes [PANC-A 2 of 8].

  • Re-biopsy recommended if adequate tissue is not available for molecular profiling in metastatic/recurrent disease [PANC-12, PANC-G 8 of 13].

  • Positive cytology from laparoscopy or laparotomy washings is equivalent to M1 disease [PANC-A 2 of 8].

  • For local recurrence after resection: consider confirmatory biopsy (category 2B), genetic testing for inherited mutations, and molecular profiling if not previously done [PANC-6].

  • ctDNA to assess minimal residual disease: recognized as emerging tool but no consensus recommendation due to limited data on how results would guide treatment decision-making [PANC-5A footnote z].

  • For patients with unresectable disease at surgery: biopsy confirmation of diagnosis if not previously done [PANC-8].

SurveillanceClick to collapse

Clinical Follow Up Schedule

  • History and physical examination for symptom assessment at each visit.
  • Frequency is typically every 3-6 months for the first 2-3 years, then every 6-12 months thereafter, though specific intervals are not mandated in the source.

Imaging Strategy

  • Chest CT and CT or MRI of the abdomen and pelvis with contrast (unless contraindicated) as clinically indicated.
  • Typically performed every 3-6 months for the first 2-3 years, then annually if no evidence of recurrence.
  • Imaging should be repeated prior to adjuvant therapy to assess for early recurrence.

Laboratory Monitoring

  • CA 19-9 level measurement is a category 2B recommendation. It should be measured after neoadjuvant treatment, prior to surgery, following surgery immediately prior to adjuvant therapy, and for surveillance.
  • CA 19-9 elevation alone, without other evidence of recurrence, is not a clear indication for treatment.
  • Liver function tests should be monitored periodically.

Supportive Follow Up

  • Nutritional assessment and support as needed.
  • Pain management and assessment.
  • Psychosocial screening and support.
  • Monitoring for and management of exocrine pancreatic insufficiency with enzyme replacement therapy.
  • Assessment for treatment-related long-term toxicities.

ComplicationsClick to collapse

Disease-Related

ComplicationManagement
Biliary ObstructionEndoscopic placement of a self-expandable metal stent (SEMS) is preferred for palliation. Percutaneous biliary drainage or surgical biliary-enteric bypass are alternatives if endoscopic access fails or is not feasible. Biliary decompression is required before initiation of neoadjuvant therapy for jaundiced patients.
Gastric Outlet ObstructionEndoscopic enteral stent placement is preferred for patients with poor performance status. Gastrojejunostomy (open or laparoscopic) may be considered for fit patients with life expectancy >3-6 months. A venting PEG tube can be used for gastric decompression in very poor prognosis patients.
Cancer-Associated Venous Thromboembolism (VTE)Low-molecular-weight heparin (LMWH) is preferred over warfarin. Direct oral anticoagulants (DOACs) may be considered for patients without luminal tumors. Prophylactic LMWH is not routinely recommended due to lack of proven survival benefit.
Severe Tumor-Associated Abdominal PainEarly referral to pain or palliative care specialist. Opioid analgesics are mainstay. EUS-guided celiac plexus neurolysis is recommended for pain refractory to opioids. Palliative radiation therapy or SBRT may be used for local control of pain. High-intensity focused ultrasound and intrathecal drug delivery are options for refractory cases.
Bleeding from Primary Tumor SiteTherapeutic endoscopy if clinically indicated. Palliative radiation therapy if not previously administered. Angiography with embolization for clinically significant bleeding.
Exocrine Pancreatic Insufficiency and MalnutritionPancreatic enzyme replacement therapy with a starting dose of at least 48,000 units lipase with meals (preferably 72,000). Nutritional evaluation with a registered dietitian. Consider proton pump inhibitors if enzyme replacement is ineffective.

Supportive CareClick to collapse

The primary goal of palliative and supportive care is to prevent and ameliorate suffering while ensuring optimal quality of life. This includes management of disease-related symptoms (e.g., biliary obstruction, pain, malnutrition) and treatment-related side effects. A multidisciplinary approach involving medical oncology, palliative care, nutrition, pain management, and psychosocial support is essential. Palliative surgical procedures are best reserved for patients with longer life expectancies.

Nutritional Support

Pancreatic exocrine enzyme replacement therapy is recommended for all patients with symptoms of exocrine insufficiency, starting with at least 48,000 units lipase with meals (preferably 72,000). A nutritional evaluation by a registered dietitian is recommended for all patients with locally advanced or metastatic disease. Nutritional support may include oral supplements, enteral feeding via jejunostomy tube, or parenteral nutrition in select cases.

Anti Emetic Protocol

Anti-emetic prophylaxis should be based on the emetogenic potential of the chemotherapy regimen used. For highly emetogenic regimens (e.g., FOLFIRINOX), a combination of a 5-HT3 receptor antagonist, dexamethasone, and an NK1 receptor antagonist is recommended. For moderately emetogenic regimens, a 5-HT3 antagonist plus dexamethasone is appropriate.

Gcsf Guidance

Growth factor support (G-CSF) should be considered for patients receiving chemotherapy regimens with a high risk of febrile neutropenia (>20%) or in patients with additional risk factors (e.g., advanced age, poor performance status, prior episodes of neutropenia). The use of pegfilgrastim is preferred for convenience.

Vte Prophylaxis

Patients with pancreatic cancer are at high risk for VTE. Treatment-dose LMWH is preferred over warfarin for established VTE. Direct oral anticoagulants (DOACs) may be considered for patients without luminal tumors. Prophylactic anticoagulation is not routinely recommended outside of a clinical trial setting due to lack of proven survival benefit.

Pain Management

Pain management should follow the NCCN Guidelines for Adult Cancer Pain. Early referral to a pain specialist is recommended. For severe tumor-associated abdominal pain refractory to opioids, EUS-guided celiac plexus neurolysis is a preferred option. Palliative radiation therapy or SBRT may be used for local control of pain. High-intensity focused ultrasound and intrathecal drug delivery are options for refractory cases.

Psychosocial Support

All patients should be screened for depression, anxiety, and distress using validated tools. Referral to palliative medicine services, social work, and psychological support is recommended. Advance care planning should be encouraged.

Dental Care

Dental care is not specifically addressed in the guidelines. However, good oral hygiene is important for patients receiving chemotherapy, and a dental evaluation may be considered prior to initiation of therapy.

PrognosisClick to collapse

Pancreatic adenocarcinoma carries a poor prognosis, with an estimated 5-year overall survival rate of 11% for all stages combined. In 2026, an estimated 67,530 people will be diagnosed with pancreatic cancer and 52,740 will die from the disease in the United States, making it the fourth leading cause of cancer-related death. Prognosis is heavily influenced by disease stage at diagnosis, with only a minority of patients presenting with localized disease amenable to curative-intent resection. Even after complete resection, recurrence rates are high. Systemic therapy has modestly improved outcomes for advanced disease, but survival remains measured in months for most patients with metastatic disease.

Overall Prognosis

By Stage

StageFive Yr SurvivalContext
Stage I (T1-3, N0, M0)Data for stage-specific 5-year survival are not explicitly provided in the source. However, patients with resectable disease (which includes most stage I) who undergo curative-intent surgery followed by adjuvant therapy have median overall survival ranging from 20.1 to 28.0 months under optimal clinical trial conditions.Includes resectable and potentially borderline resectable tumors. Treatment involves surgery with or without neoadjuvant/adjuvant therapy.
Stage II (T1-3, N1, M0 or T3, N0, M0)Not explicitly provided. Survival is intermediate, heavily dependent on nodal status (N1 vs N2) and response to therapy.Often borderline resectable or locally advanced. Multimodality therapy including neoadjuvant/induction chemotherapy and possible chemoradiation is standard.
Stage III (Any T, N2, M0 or T4, Any N, M0)Not explicitly provided. Prognosis is poor for locally advanced disease, with median overall survival typically 12-18 months with modern systemic regimens.Locally advanced, unresectable disease. Primary treatment is systemic therapy with possible consolidation chemoradiation or SBRT.
Stage IV (Any T, Any N, M1)Less than 3%. Median overall survival with first-line chemotherapy ranges from approximately 6.8 to 12.1 months depending on regimen and performance status.Metastatic disease. Treatment is palliative systemic therapy with a goal of prolonging survival and maintaining quality of life.

Prognostic Factors

  • Resection status (R0 vs. R1/R2) is a major prognostic factor for resected disease.
  • Lymph node involvement (N1/N2 status and lymph node ratio) strongly influences prognosis after resection.
  • Tumor size and T-stage.
  • Performance status (ECOG 0-1 vs. 2-3) is critical for tolerating therapy and survival in advanced disease.
  • CA 19-9 levels: elevated baseline levels and failure to normalize with treatment are associated with poorer outcomes.
  • Presence of specific molecular alterations (e.g., germline BRCA1/2 mutations, MSI-H/dMMR) may influence response to specific therapies and thus prognosis.
  • Disease stage at presentation (resectable, borderline resectable, locally advanced, metastatic).

Follow UpClick to collapse

Post Curative Treatment

Following curative-intent surgery, patients should undergo a baseline postoperative CT (chest, abdomen, and pelvis) with contrast and measurement of CA 19-9. If not previously done, genetic testing for inherited mutations, biopsy confirmation, and molecular profiling should be performed. Adjuvant therapy should be initiated within 12 weeks of recovery from surgery. The preferred adjuvant regimen is modified FOLFIRINOX or capecitabine/gemcitabine.

Surveillance Rationale

The rationale for surveillance is the early detection of recurrence, which may allow for potential enrollment in clinical trials or other forms of treatment. However, data on the effectiveness of surveillance in improving overall survival are limited. Earlier identification of recurrence is a consensus goal.

Late Effects Screening

  • Monitor for treatment-related toxicities, such as peripheral neuropathy (from oxaliplatin or paclitaxel), renal dysfunction (from cisplatin), and cardiotoxicity (from specific agents).
  • Screen for post-pancreatectomy diabetes and exocrine insufficiency, which may require ongoing enzyme replacement.
  • Screen for nutritional deficiencies and malnutrition.
  • Monitor for psychological distress, depression, and fatigue.

Recurrence Patterns

Recurrence after resection can be local (pancreatic bed), regional (lymph nodes), or distant (metastatic). The most common site of recurrence for patients followed for 5 years is the lungs. Patterns of recurrence can be influenced by tumor stage, margin status, and lymph node involvement.

Key TrialsClick to collapse

AcronymFull NameYearNInterventionComparatorPopulationPrimary EndpointKey ResultSecondary OutcomesPractice ChangeJournal
PRODIGE 4/ACCORD 11Unicancer PRODIGE 4/ACCORD 11 trial2011342FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, leucovorin)GemcitabineMetastatic pancreatic cancer, good PS (ECOG 0-1)Overall survivalMedian OS 11.1 vs 6.8 months (HR 0.57, P<0.001); Median PFS 6.4 vs 3.3 months (P<0.001).ORR 31.6% vs 9.4%; 1-year survival 48.4% vs 20.6%.Established FOLFIRINOX as a preferred first-line regimen for metastatic pancreatic cancer in good PS patients.New England Journal of Medicine
MPACTMetastatic Pancreatic Adenocarcinoma Clinical Trial2013861Albumin-bound paclitaxel plus gemcitabineGemcitabineMetastatic pancreatic cancer, KPS β‰₯70Overall survivalMedian OS 8.5 vs 6.7 months (HR 0.72, P<0.001).ORR 23% vs 7%; Median PFS 5.5 vs 3.7 months.Established albumin-bound paclitaxel/gemcitabine as a category 1 preferred first-line regimen for metastatic disease.New England Journal of Medicine
ESPAC-4European Study Group for Pancreatic Cancer - 42017730Gemcitabine plus capecitabineGemcitabineResected pancreatic cancer, no prior neoadjuvant therapyOverall survivalMedian OS 28.0 vs 25.5 months (HR 0.82, 95% CI 0.68-0.98, P=0.032).3-year survival 49.1% vs 41.4%.Established capecitabine/gemcitabine as a preferred adjuvant regimen for resected pancreatic cancer (category 1).Lancet
PRODIGE 24/CCTG PA.6Unicancer PRODIGE 24/CCTG PA.6 trial2021493Modified FOLFIRINOXGemcitabineResected pancreatic cancer, good PSDisease-free survivalMedian DFS 21.6 vs 12.8 months (HR 0.58, P<0.001); Median OS 53.5 vs 35.5 months (HR 0.64, P=0.003).5-year DFS 26.1% vs 19.0%.Established modified FOLFIRINOX as a preferred adjuvant regimen for resected pancreatic cancer in good PS patients (category 1).New England Journal of Medicine
CONKO-001CharitΓ© Onkologie 001 trial2013368GemcitabineObservationResected pancreatic cancer, no prior chemotherapy/RTDisease-free survivalMedian DFS 13.4 vs 6.9 months (P<0.001); Median OS 22.8 vs 20.2 months (HR 0.76, P=0.01).5-year survival 20.7% vs 10.4%.Established adjuvant gemcitabine as a standard of care for resected pancreatic cancer.JAMA
NAPOLI-3NAPOLI 3: Nanoliposomal Irinotecan Study2023770NALIRIFOX (liposomal irinotecan, 5-FU/leucovorin, oxaliplatin)Albumin-bound paclitaxel plus gemcitabineMetastatic pancreatic ductal adenocarcinoma, first-lineOverall survivalMedian OS 11.1 vs 9.2 months (HR 0.84, P=0.04).Median PFS 7.4 vs 5.6 months (HR 0.69, P=0.0003).Established NALIRIFOX as a category 1 preferred first-line regimen for metastatic disease, with the caveat that it does not appear to have an advantage over FOLFIRINOX.Lancet
POLOOlaparib Maintenance Therapy for BRCA-Mutated Metastatic Pancreatic Cancer2019154Olaparib maintenancePlaceboMetastatic pancreatic cancer with germline BRCA1/2 mutation, no progression after β‰₯16 weeks of platinum-based first-line chemotherapyProgression-free survivalMedian PFS 7.4 vs 3.8 months (HR 0.53, 95% CI 0.35-0.82, P=0.004).No significant OS difference at interim analysis (18.9 vs 16.1 months, HR 0.91, P=0.68).Established olaparib as a preferred maintenance therapy for germline BRCA1/2-mutated metastatic pancreatic cancer after platinum-based first-line therapy.New England Journal of Medicine
LAP-07Locally Advanced Pancreatic Cancer 072016269Chemoradiation (capecitabine) vs continuation of chemotherapyChemotherapy aloneLocally advanced pancreatic cancer controlled after 4 months of gemcitabine Β± erlotinibOverall survivalNo significant OS difference (HR 1.03, 95% CI 0.79-1.34, P=0.83).No significant PFS difference (HR 0.87, 95% CI 0.67-1.13).Based on trial data, there is no clear survival benefit with addition of conventional chemoradiation following gemcitabine monotherapy in locally advanced disease. Chemoradiation may improve local control and delay need for resumption therapy.JAMA

Clinical PearlsClick to collapse

  • Pearl 1: Multidisciplinary consultation at a high-volume center is essential for optimal management of all pancreatic cancer patients, impacting staging, surgical candidacy, and treatment planning.
  • Pearl 2: High-quality dedicated pancreatic protocol CT (or MRI) is the cornerstone for staging and resectability assessment. The use of a standardized radiology reporting template is recommended.
  • Pearl 3: CA 19-9 is a useful biomarker but must be interpreted with caution. It can be elevated due to biliary obstruction, cholangitis, or inflammation, and is undetectable in Lewis antigen-negative individuals. Best measured after biliary decompression.
  • Pearl 4: For borderline resectable disease, neoadjuvant therapy is now the standard of care approach at most NCCN member institutions, with upfront surgery no longer recommended.
  • Pearl 5: Resection should be performed at high-volume centers (β‰₯15-20 pancreatic resections annually) to optimize surgical outcomes, including lower perioperative mortality and higher R0 resection rates.
  • Pearl 6: Molecular profiling using next-generation sequencing (NGS) is recommended for all patients with advanced disease who are candidates for anti-cancer therapy, to identify actionable alterations (e.g., BRCA1/2, MSI-H, NTRK fusion, BRAF V600E).
  • Pearl 7: Immunotherapy is highly effective for the small subset of pancreatic cancers with MSI-H/dMMR tumors, making molecular testing imperative.
  • Pearl 8: Germline BRCA1/2 testing is recommended for all patients with confirmed pancreatic cancer, as it has implications for treatment (platinum sensitivity, PARP inhibition) and for familial screening.
  • Pearl 9: Supportive care is integral to management, including biliary stenting for obstruction, celiac plexus neurolysis for pain, pancreatic enzyme replacement for exocrine insufficiency, and nutritional support.
  • Pearl 10: The role of ctDNA for minimal residual disease detection is emerging but not yet standard for guiding adjuvant therapy decisions.

Special SituationsClick to collapse

Borderline Resectable Disease
Locally Advanced Disease
Metastatic Disease
Recurrent Disease After Resection
BRCA1/2 or PALB2 Mutations
MSI-H/dMMR Tumors
BRAF V600E Mutation
NTRK Gene Fusion
HER2 Overexpression (IHC3+ or IHC2+ with FISH HER2 amplified)

Guidelines ResourcesClick to collapse

NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma
NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities
NCCN Guidelines for Palliative Care
AJCC Cancer Staging Manual, 8th Edition
Cancer Protocol Template for Carcinoma of the Pancreas

Protective FactorsClick to collapse

  • High levels of regular physical activity (associated with a 7% reduced risk compared to low activity, RR 0.93, 95% CI 0.88-0.98).
  • Metformin use in diabetic patients (may reduce risk, though evidence is mixed and confounded by the underlying diabetes).
  • Potential protective effects of certain dietary components (e.g., fruits, vegetables) though data are not consistent.